VPC70063 is a novel and potent Myc-Max inhibitor (IC50 = 8.9 μM).

EN4 is a novel and potent MYC inhibitor that targets cysteine 171 .

ML327 is a novel potent MYC blocker which also de-represses E-cadherin transcription, partially reverses EMT (Epithelial-to-Mesenchymal Transition), and inhibits cancer cell invasiveness and tumor cell migration in vitro and in vivo.

10074-G5 is a potent inhibitor of c-Myc-Max dimerization and interaction with an IC50 of 146 μM and with anticancer activities.

MYCi361 (NUCC0196361) is a novel and potent MYC inhibitor (Kd = 3.2 μM) with potential anticancer activity, it demonstrated a narrow therapeutic index. MYCi361 engaged MYC inside cells, disrupted MYC/MAX dimers, and impaired MYC-driven gene expression.

MYCi975 (NUCC-0200975), an MYCi361 analog, is a novel, orally bioactive and potent MYC inhibitor (Kd = 3.2 μM) with potential anticancer activity.

Mycro3 is a novel, potent and selective inhibitor of Myc-Max dimerization in cell-based assays.

10058-F4 (10058F4; 10058 F4) is a novel potent and selective c-Myc inhibitor with potential antineoplastic activity.